explore -WSS

explore

author：fashion 2025-10-02 12:31:59 - browse：761

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

WSS

Will the market for weight loss drugs really reach $100 billion?

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

ReNAgade cuts staff seven months after raising $300 million

ReNAgade cuts staff seven months after raising $300 million

Rep. Raul Ruiz on the physician shortage and more

FDA investigates CAR

knowledge

explore

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth’s Optum accused of antitrust violations in California

Activists slam private health insurers over coverage restrictions

How to pay for weight loss drugs and save Medicare

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC director unscathed in first congressional testimony

Peter Hotez and the public health issue of online harassment

Scientific mystery highlights the blind spots in genomics databases

How one medical school became remarkably diverse

Scientific mystery highlights the blind spots in genomics databases

focus

ReNAgade cuts staff seven months after raising $300 million

Despite FDA concern, risk that CAR

U.K. decision on ALS drug has neurologists, advocates up in arms

J&J to emphasize cancer drugs, stop much of its vaccine research

Bird flu reported in person exposed to presumably infected cattle

ReNAgade cuts staff seven months after raising $300 million

Wikipedia

focus

knowledge

entertainment